Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Dose-Escalation Study to Evaluate the Tolerability, DLT, Pharmacokinetics, and Preliminary Efficacy of HF1K16 in Patients With Refractory Solid Tumors

NCT05388487 is registered in ClinicalTrials.gov with HighField Biopharmaceuticals Corporation as lead sponsor.

NCT NCT05388487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05388487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Dose-Escalation Study to Evaluate the Tolerability, DLT, Pharmacokinetics, and Preliminary Efficacy of HF1K16 in Patients With Refractory Solid Tumors
Lead sponsor
HighField Biopharmaceuticals Corporation
Phase
Phase 1
Overall status
Unknown status
Start date
February 16, 2022
Completion date
November 30, 2025
Enrollment
54 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult